<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMIVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
<ATC code="J05AR02" />
<ATC code="J05AR07" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLADRIBINE" rxcui="44157">
<ATC code="L01BB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cladribine by the lamivudine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMIVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
<ATC code="J05AR02" />
<ATC code="J05AR07" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
